{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:25Z","timestamp":1793836465184,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Corticosteroids may produce a paradoxical worsening of myasthenia gravis (MG) symptoms within the first weeks of treatment. We therefore wanted to assess the hypothesis that a prior infusion of intravenous immunoglobulin (IVIG) may have a protective effect. Our primary objectives were to show that the coadministration of immunoglobulins and glucocorticoids is safe and effective for controlling myasthenic symptoms, and to compare the exacerbation rate with this approach and historical practice without IVIG. We recruited 45 patients with generalized MG who required corticosteroids for the first time and we gave all IVIG before starting the full doses of prednisone. Monitoring was performed with validated scales, questionnaires, and blood tests over a 6-week period. Only 4.4% had severe adverse effects related to IVIG and 86.7% improved clinically. Notably, only 2.2% had a paradoxical symptom exacerbation in the first weeks of starting prednisone, which was statistically lower than the 42% reported in a historical series. We conclude that adjuvant therapy with IVIG when starting prednisone for the first time in patients with generalized MG is safe and effective. Given that the rate of paradoxical worsening was lower than that previously reported, the addition of IVIG may have a protective effect against such exacerbations.<\/jats:p>","DOI":"10.1038\/s41598-020-70539-4","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T06:05:13Z","timestamp":1597125913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis"],"prefix":"10.1038","volume":"10","author":[{"given":"Laura","family":"D\u00edez-Porras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"V\u00e9lez-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"70539_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","volume":"32","author":"JM Aragon\u00e8s","year":"2017","unstructured":"Aragon\u00e8s, J. M. et al. Prevalence of myasthenia gravis in the Catalan county of Osona. Neurologia32, 1\u20135. https:\/\/doi.org\/10.1016\/j.nrl.2014.09.007 (2017).","journal-title":"Neurologia"},{"key":"70539_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","volume":"36","author":"DB Drachman","year":"2016","unstructured":"Drachman, D. B. Myasthenia gravis. Semin. Neurol.36, 419\u2013424. https:\/\/doi.org\/10.1055\/s-0036-1586265 (2016).","journal-title":"Semin. Neurol."},{"key":"70539_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Disease Primers5, 30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y (2019).","journal-title":"Nat. Rev. Disease Primers"},{"key":"70539_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-829593","volume":"24","author":"LH Phillips","year":"2004","unstructured":"Phillips, L. H. The epidemiology of myasthenia gravis. Semin. Neurol.24, 17\u201320. https:\/\/doi.org\/10.1055\/s-2004-829593 (2004).","journal-title":"Semin. Neurol."},{"key":"70539_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mus.1221","volume":"25","author":"RS Bedlack","year":"2002","unstructured":"Bedlack, R. S. & Sanders, D. B. Steroids have an important role. Muscle Nerve25, 117\u2013121. https:\/\/doi.org\/10.1002\/mus.1221 (2002).","journal-title":"Muscle Nerve"},{"key":"70539_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/wnl.22.6.603","volume":"22","author":"NG Brunner","year":"1972","unstructured":"Brunner, N. G., Namba, T. & Grob, D. Corticosteroids in management of severe, generalized myasthenia gravis: Effectiveness and comparison with corticotrophin therapy. Neurology22, 603\u2013610. https:\/\/doi.org\/10.1212\/wnl.22.6.603 (1972).","journal-title":"Neurology"},{"key":"70539_CR7","first-page":"29","volume":"2","author":"CS Chung","year":"1984","unstructured":"Chung, C. S. & Myung, H. J. A clinical study on crisis in myasthenia gravis. J. Korean Neurol. Assoc.2, 29\u201339 (1984).","journal-title":"J. Korean Neurol. Assoc."},{"key":"70539_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.7326\/0003-4819-52-4-806","volume":"52","author":"LD Freydberg","year":"1960","unstructured":"Freydberg, L. D. The place of corticotropin in the treatment of myasthenia gravis. Ann. Intern. Med.52, 806\u2013818. https:\/\/doi.org\/10.7326\/0003-4819-52-4-806 (1960).","journal-title":"Ann. Intern. Med."},{"key":"70539_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0140-6736(72)90520-X","volume":"299","author":"RB Jenkins","year":"1972","unstructured":"Jenkins, R. B. Treatment of Myasthenia gravis with prednisone. Lancet299, 765\u2013767 (1972).","journal-title":"Lancet"},{"key":"70539_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-0404.1971.tb07501.x","volume":"47","author":"M Kj\u00e6r","year":"1971","unstructured":"Kj\u00e6r, M. Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol. Scand.47, 464\u2013474. https:\/\/doi.org\/10.1111\/j.1600-0404.1971.tb07501.x (1971).","journal-title":"Acta Neurol. Scand."},{"key":"70539_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli, M. N. & Sanders, D. B. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol.8, 475\u2013490. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8 (2009).","journal-title":"Lancet Neurol."},{"key":"70539_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM197201062860104","volume":"286","author":"JR Warmolts","year":"1972","unstructured":"Warmolts, J. R. & Engel, W. K. Benefit from alternate-day prednisone in myasthenia gravis. N. Engl. J. Med.286, 17\u201320. https:\/\/doi.org\/10.1056\/NEJM197201062860104 (1972).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"70539_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0733-8619(05)70013-x","volume":"19","author":"DS Younger","year":"2001","unstructured":"Younger, D. S. & Raksadawan, N. Therapy in neuromuscular disease. Neurol. Clin.19(1), 205\u2013215. https:\/\/doi.org\/10.1016\/s0733-8619(05)70013-x (2001).","journal-title":"Neurol. Clin."},{"key":"70539_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman, D. B. Myasthenia gravis. N. Engl. J. Med.330, 1797\u20131810. https:\/\/doi.org\/10.1056\/NEJM199406233302507 (1994).","journal-title":"N. Engl. J. Med."},{"key":"70539_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/wnl.26.8.729","volume":"26","author":"JD Mann","year":"1976","unstructured":"Mann, J. D., Johns, T. R. & Campa, J. F. Long-term administration of corticosteroids in myasthenia gravis. Neurology26, 729\u2013740. https:\/\/doi.org\/10.1212\/wnl.26.8.729 (1976).","journal-title":"Neurology"},{"key":"70539_CR16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace, J., Newsom-Davis, J. & Lecky, B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology50, 1778\u20131783. https:\/\/doi.org\/10.1212\/wnl.50.6.1778 (1998).","journal-title":"Neurology"},{"key":"70539_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi, R. M., Coslett, H. B. & Johns, T. R. Long-term corticosteriod treatment of myasthenia gravis: Report of 116 Patients. Ann. Neurol.15, 291\u2013298. https:\/\/doi.org\/10.1002\/ana.410150316 (1984).","journal-title":"Ann. Neurol."},{"key":"70539_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","volume":"290","author":"ME Seybold","year":"1974","unstructured":"Seybold, M. E. & Drachman, D. B. Gradually increasing doses of prednisone in myasthenia gravis: Reducing the hazards of treatment. N. Engl. J. Med.290, 81\u201384. https:\/\/doi.org\/10.1056\/NEJM197401102900204 (1974).","journal-title":"N. Engl. J. Med."},{"key":"70539_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae, J. S., Go, S. M. & Kim, B. J. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J. Clin. Neurosci.13, 1006\u20131010. https:\/\/doi.org\/10.1016\/j.jocn.2005.12.041 (2006).","journal-title":"J. Clin. Neurosci."},{"key":"70539_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1172\/JCI102157","volume":"28","author":"C Torda","year":"1949","unstructured":"Torda, C. & Wolff, H. G. Effects of adrenocorticotrophic hormone on neuromuscular function in patients with myasthenia gravis 1. J. Clin. Invest.28, 1228\u20131235 (1949).","journal-title":"J. Clin. Invest."},{"key":"70539_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","volume":"63","author":"MJ Herold","year":"2006","unstructured":"Herold, M. J., McPherson, K. G. & Reichardt, H. M. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci.63, 60\u201372. https:\/\/doi.org\/10.1007\/s00018-005-5390-y (2006).","journal-title":"Cell. Mol. Life Sci."},{"key":"70539_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-005-0001-7","volume":"7","author":"VC Juel","year":"2005","unstructured":"Juel, V. C. & Massey, J. M. Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation. Curr. Treat. Options Neurol.7, 3\u201314. https:\/\/doi.org\/10.1007\/s11940-005-0001-7 (2005).","journal-title":"Curr. Treat. Options Neurol."},{"key":"70539_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s0140-6736(84)90469-0","volume":"323","author":"P Gajdos","year":"1984","unstructured":"Gajdos, P. et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet323, 406\u2013407. https:\/\/doi.org\/10.1016\/s0140-6736(84)90469-0 (1984).","journal-title":"Lancet"},{"key":"70539_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman, L., Ng, E. & Bril, V. IV. immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology68, 837\u2013841. https:\/\/doi.org\/10.1212\/01.wnl.0000256698.69121.45 (2007).","journal-title":"Neurology"},{"key":"70539_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth, D., Nouri, M. N., Ng, E., Nwe, P. & Bril, V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology76, 2017\u20132023. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505 (2011).","journal-title":"Neurology"},{"key":"70539_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos, P., Chevret, S., Clair, B., Tranchant, C. & Chastang, C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol.41, 789\u2013796. https:\/\/doi.org\/10.1002\/ana.410410615 (1997).","journal-title":"Ann. Neurol."},{"key":"70539_CR27","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos, P. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial. Arch. Neurol.62, 1689\u20131693. https:\/\/doi.org\/10.1001\/archneur.62.11.1689 (2005).","journal-title":"Arch. Neurol."},{"key":"70539_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/wnl.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi, A. I. et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology52, 629\u2013632. https:\/\/doi.org\/10.1212\/wnl.52.3.629 (1999).","journal-title":"Neurology"},{"key":"70539_CR29","first-page":"2404","volume":"20","author":"MG Wang","year":"2016","unstructured":"Wang, M. G., Huang, X. X., Yao, D., An, Q. & Deng, X. Q. Effect of glucocorticoid combined with gamma globulin in treatment of children with myasthenia gravis and its effects on immune globulin and complement of children. Eur. Rev. Med. Pharmacol. Sci.20, 2404\u20132408 (2016).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"70539_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara, I. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol.15, 893\u2013908. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02246.x (2008).","journal-title":"Eur. J. Neurol."},{"key":"70539_CR31","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1586\/1744666X.2014.971757","volume":"10","author":"M Alabdali","year":"2014","unstructured":"Alabdali, M., Barnett, C., Katzberg, H., Breiner, A. & Bril, V. Intravenous immunoglobulin as treatment for myasthenia gravis: Current evidence and outcomes. Expert. Rev. Clin. Immunol.10, 1659\u20131665. https:\/\/doi.org\/10.1586\/1744666X.2014.971757 (2014).","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"70539_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419864497","author":"J Gamez","year":"2019","unstructured":"Gamez, J. et al. Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther. Adv. Neurol. Disord.\nhttps:\/\/doi.org\/10.1177\/1756286419864497 (2019).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"70539_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","volume":"261","author":"A Jani-Acsadi","year":"2007","unstructured":"Jani-Acsadi, A. & Lisak, R. P. Myasthenic crisis: Guidelines for prevention and treatment. J. Neurol. Sci.261, 127\u2013133. https:\/\/doi.org\/10.1016\/j.jns.2007.04.045 (2007).","journal-title":"J. Neurol. Sci."},{"key":"70539_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders, D. B. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology87, 419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790 (2016).","journal-title":"Neurology"},{"key":"70539_CR35","unstructured":"MGFA Clinical Classification. https:\/\/www.myasthenia.org\/LinkClick.aspx?fileticket=sIitErMYbkA%3d&tabid=125. Accessed 1 April 2016"},{"key":"70539_CR36","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard, J. F. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol.16, 976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1 (2017).","journal-title":"Lancet Neurol."},{"key":"70539_CR37","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","volume":"78","author":"HS Patwa","year":"2012","unstructured":"Patwa, H. S., Chaudhry, V., Katzberg, H., Rae-Grant, A. D. & So, Y. T. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology78, 1009\u20131015. https:\/\/doi.org\/10.1212\/WNL.0b013e31824de293 (2012).","journal-title":"Neurology"},{"key":"70539_CR38","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn, R. J. et al. Reliability testing of the quantitative myasthenia gravis score. Ann. N. Y. Acad. Sci.841, 769\u2013772. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"70539_CR39","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe, G. I. et al. Myasthenia gravis activities of daily living profile. Neurology52, 1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487 (1999).","journal-title":"Neurology"},{"key":"70539_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","volume":"1274","author":"S Muppidi","year":"2012","unstructured":"Muppidi, S. The myasthenia gravis-specific activities of daily living profile. Ann. N. Y. Acad. Sci.1274, 114\u2013119. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06817.x (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"70539_CR41","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns, T. M., Conaway, M. & Sanders, D. B. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology74, 1434\u20131440. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e (2010).","journal-title":"Neurology"},{"key":"70539_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","volume":"43","author":"TM Burns","year":"2011","unstructured":"Burns, T. M., Grouse, C. K., Wolfe, G. I., Conaway, M. R. & Sanders, D. B. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve43, 14\u201318. https:\/\/doi.org\/10.1002\/mus.21883 (2011).","journal-title":"Muscle Nerve"},{"key":"70539_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2012.06812.x","volume":"1274","author":"TM Burns","year":"2012","unstructured":"Burns, T. M. The MG composite: An outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann. N. Y. Acad. Sci.1274, 99\u2013106. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06812.x (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"70539_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","volume":"49","author":"HD Katzberg","year":"2014","unstructured":"Katzberg, H. D., Barnett, C., Merkies, I. S. J. & Bril, V. Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. Muscle Nerve49, 661\u2013665. https:\/\/doi.org\/10.1002\/mus.23988 (2014).","journal-title":"Muscle Nerve"},{"key":"70539_CR45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.wnl.0000050461.05432.c5","volume":"60","author":"JM Aragon\u00e8s","year":"2003","unstructured":"Aragon\u00e8s, J. M. et al. Myasthenia gravis: A higher than expected incidence in the elderly. Neurology60, 1024\u20131026. https:\/\/doi.org\/10.1212\/01.wnl.0000050461.05432.c5 (2003).","journal-title":"Neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70539-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:26:20Z","timestamp":1670329580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70539-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70539"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70539-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13497"}}